RESUMO
Vaccination against infectious diseases has changed the future of the human species, saving millions of lives every year, both children and adults, and providing major benefits to society as a whole. Here we show, however, that national and sub-national coverage of vaccination varies greatly and major unmet needs persist. Although scientific progress opens exciting perspectives in terms of new vaccines, the pathway from discovery to sustainable implementation can be long and difficult, from the financing, development and licensing to programme implementation and public acceptance. Immunization is one of the best investments in health and should remain a priority for research, industry, public health and society.
Assuntos
Desenvolvimento de Medicamentos/economia , Vacinação/tendências , Vacinas/imunologia , Vacinas/provisão & distribuição , Animais , Humanos , Mortalidade , Filipinas/epidemiologia , Mudança Social , Vacinação/economia , Vacinas/economiaAssuntos
Antibacterianos , Desenvolvimento de Medicamentos , Apoio à Pesquisa como Assunto , Humanos , Antibacterianos/classificação , Antibacterianos/economia , Antibacterianos/provisão & distribuição , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/legislação & jurisprudência , Farmacorresistência Bacteriana , Apoio à Pesquisa como Assunto/economia , Apoio à Pesquisa como Assunto/legislação & jurisprudênciaAssuntos
Custos de Medicamentos , Desenvolvimento de Medicamentos , Peptídeos Semelhantes ao Glucagon , Obesidade , Humanos , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/tendências , Peptídeos Semelhantes ao Glucagon/economia , Peptídeos Semelhantes ao Glucagon/uso terapêutico , Obesidade/tratamento farmacológicoRESUMO
The promise of drug repurposing is to accelerate the translation of knowledge to treatment of human disease, bypassing common challenges associated with drug development to be more time- and cost-efficient. Repurposing has an increased chance of success due to the previous validation of drug safety and allows for the incorporation of omics. Hypothesis-generating omics processes inform drug repurposing decision-making methods on drug efficacy and toxicity. This review summarizes drug repurposing strategies and methodologies in the context of the following omics fields: genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, phenomics, pregomics, and personomics. While each omics field has specific strengths and limitations, incorporating omics into the drug repurposing landscape is integral to its success.
Assuntos
Reposicionamento de Medicamentos/métodos , Preparações Farmacêuticas/administração & dosagem , Animais , Tomada de Decisões , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/métodos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle , HumanosRESUMO
Clinical research should conform to high standards of ethical and scientific integrity, given that human lives are at stake. However, economic incentives can generate conflicts of interest for investigators, who may be inclined to withhold unfavorable results or even tamper with data in order to achieve desired outcomes. To shed light on the integrity of clinical trial results, this paper systematically analyzes the distribution of P values of primary outcomes for phase II and phase III drug trials reported to the ClinicalTrials.gov registry. First, we detect no bunching of results just above the classical 5% threshold for statistical significance. Second, a density-discontinuity test reveals an upward jump at the 5% threshold for phase III results by small industry sponsors. Third, we document a larger fraction of significant results in phase III compared to phase II. Linking trials across phases, we find that early favorable results increase the likelihood of continuing into the next phase. Once we take into account this selective continuation, we can explain almost completely the excess of significant results in phase III for trials conducted by large industry sponsors. For small industry sponsors, instead, part of the excess remains unexplained.
Assuntos
Ensaios Clínicos como Assunto/economia , Ensaios Clínicos como Assunto/normas , Relatório de Pesquisa/normas , Pesquisa Biomédica/economia , Ensaios Clínicos como Assunto/estatística & dados numéricos , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/organização & administração , Indústria Farmacêutica/economia , Humanos , Sistema de Registros , Apoio à Pesquisa como AssuntoRESUMO
Globally, nearly half of all pregnancies are unplanned. Male contraceptives offer the potential to decrease unintended pregnancy and introduce contraceptive equity, but decades of research have yet to bring a novel product to market. New funding avenues from the philanthropic sector seek to stimulate research in male contraceptives through investments, grants, and support for trainees alongside other programs that encourage product development and ultimately commercialization. This Forum outlines the purpose of and funding opportunities provided by Male Contraceptive Initiative, a funding agency and non-profit focused on the advancement of non-hormonal, reversible contraceptive technologies for those who produce sperm.
Assuntos
Anticoncepcionais Masculinos , Anticoncepcionais Masculinos/economia , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/tendências , Feminino , Humanos , Masculino , Organizações sem Fins Lucrativos , Gravidez , Gravidez não Planejada , Apoio à Pesquisa como AssuntoAssuntos
Antivirais/economia , Antivirais/provisão & distribuição , Tratamento Farmacológico da COVID-19 , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/organização & administração , Investimentos em Saúde , Monofosfato de Adenosina/análogos & derivados , Alanina/análogos & derivados , Antivirais/uso terapêutico , COVID-19/economia , Humanos , Pandemias/economia , Estoque Estratégico/economiaAssuntos
Tratamento Farmacológico da COVID-19 , Vacinas contra COVID-19 , Indústria Farmacêutica/economia , Medicamentos Genéricos/economia , Medicamentos Genéricos/provisão & distribuição , Licenciamento , Patentes como Assunto , COVID-19/economia , Vacinas contra COVID-19/economia , Vacinas contra COVID-19/provisão & distribuição , Desenvolvimento de Medicamentos/economia , Humanos , Licenciamento/legislação & jurisprudência , Patentes como Assunto/legislação & jurisprudência , Organização Mundial da Saúde/organização & administraçãoAssuntos
Antineoplásicos , Custos de Medicamentos , Desenvolvimento de Medicamentos , Medicare , Neoplasias , Idoso , Humanos , Antineoplásicos/economia , Antineoplásicos/uso terapêutico , Custos de Medicamentos/legislação & jurisprudência , Medicare/economia , Medicare/legislação & jurisprudência , Negociação , Neoplasias/tratamento farmacológico , Estados Unidos , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/legislação & jurisprudência , Fatores de TempoRESUMO
This minireview addresses problems of financing the vaccine development, regulatory questions, the ethics and efficacy of vaccine prioritization strategies and the coverage of variant viruses by current vaccines. Serious adverse effects observed with adenovirus vectored vaccines and mRNA vaccines in mass vaccination campaigns are reported. The ethical problems of continuing with placebo controlled vaccine trials and alternative clinical trial protocols are discussed as well as concrete vaccination issues such as the splitting of doses, the delaying of the second dose, the immunization with two different vaccine types and the need of vaccinating seropositive subjects. Strategies to increase vaccine acceptance in the population are shortly mentioned.
Assuntos
COVID-19/prevenção & controle , Vacinação , Vacinas contra COVID-19/administração & dosagem , Vacinas contra COVID-19/efeitos adversos , Vacinas contra COVID-19/genética , Vacinas contra COVID-19/imunologia , Ensaios Clínicos como Assunto , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/legislação & jurisprudência , Variação Genética , Prioridades em Saúde , Humanos , SARS-CoV-2/genética , SARS-CoV-2/imunologia , Vacinação/economia , Vacinação/legislação & jurisprudência , Vacinação/métodosAssuntos
Anticoncepção/métodos , Anticoncepção/tendências , Desenvolvimento de Medicamentos , Necessidades e Demandas de Serviços de Saúde , Saúde Reprodutiva/tendências , Desenvolvimento Sustentável , Saúde da Mulher/tendências , Preservativos , Anticoncepção/economia , Anticoncepcionais Femininos/efeitos adversos , Anticoncepcionais Femininos/economia , Desenvolvimento de Medicamentos/economia , Indústria Farmacêutica/economia , Feminino , Objetivos , Humanos , Invenções/economia , Investimentos em Saúde , Responsabilidade Legal , Masculino , National Institutes of Health (U.S.)/economia , Parcerias Público-Privadas/economia , Saúde Reprodutiva/economia , Estados Unidos , Saúde da Mulher/economiaAssuntos
Monofosfato de Adenosina/análogos & derivados , Alanina/análogos & derivados , Antivirais/provisão & distribuição , Infecções por Coronavirus/tratamento farmacológico , Desenvolvimento de Medicamentos , Indústria Farmacêutica/métodos , Pneumonia Viral/tratamento farmacológico , Monofosfato de Adenosina/síntese química , Monofosfato de Adenosina/provisão & distribuição , Alanina/síntese química , Alanina/provisão & distribuição , Anticorpos Monoclonais Humanizados/biossíntese , Anticorpos Monoclonais Humanizados/economia , Antivirais/síntese química , COVID-19 , Infecções por Coronavirus/economia , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/métodos , Indústria Farmacêutica/economia , Humanos , Hidroxicloroquina/síntese química , Hidroxicloroquina/provisão & distribuição , Oseltamivir/provisão & distribuição , Pandemias/economia , Pneumonia Viral/economiaRESUMO
Healthcare resource allocation decisions made under conditions of uncertainty may turn out to be suboptimal. In a resource constrained system in which there is a fixed budget, these suboptimal decisions will result in health loss. Consequently, there may be value in reducing uncertainty, through the collection of new evidence, to make better resource allocation decisions. This value can be quantified using a value of information (VOI) analysis. This report, from the ISPOR VOI Task Force, introduces VOI analysis, defines key concepts and terminology, and outlines the role of VOI for supporting decision making, including the steps involved in undertaking and interpreting VOI analyses. The report is specifically aimed at those tasked with making decisions about the adoption of healthcare or the funding of healthcare research. The report provides a number of recommendations for good practice when planning, undertaking, or reviewing the results of VOI analyses.
Assuntos
Orçamentos , Tomada de Decisões , Técnicas de Apoio para a Decisão , Custos de Medicamentos , Desenvolvimento de Medicamentos/economia , Alocação de Recursos para a Atenção à Saúde/economia , Pesquisa sobre Serviços de Saúde/economia , Avaliação da Tecnologia Biomédica/economia , Redução de Custos , Análise Custo-Benefício , Humanos , Reembolso de Seguro de Saúde/economia , Modelos Econômicos , Modelos Estatísticos , Formulação de Políticas , Seguro de Saúde Baseado em Valor/economia , Aquisição Baseada em Valor/economiaRESUMO
BACKGROUND: Changes in the regulatory context enable faster approval of transformative medicines. They also lead to health technology assessment (HTA) agencies having to make decisions with less evidence. In response, HTA agencies have also initiated forms of conditional approval. When the evidence base for a new oncology treatment leaves substantial uncertainty, the new Cancer Drugs Fund allows the National Institute for Heath and Care Excellence to give the manufacturer two options: (1) offer a low price based on conservative assumptions and obtain immediate approval ("stick") or (2) wait until the evidence base has further matured before finalizing a potentially higher agreed price ("twist"). OBJECTIVES: The purpose of this article is to explain how, using the theoretical framework of the expected value of sample information, simulation methods can help inform a manufacturer's decisions when faced with the option to stick or twist. METHODS: We first summarize a general model to help frame the manufacturer's negotiating strategy. We then use a motivating case study, based on a hypothetical immunotherapy, to illustrate how manufacturers can use simulation methods to robustly characterize the uncertainty inherent to further data collection and incorporate this uncertainty within their decision making. RESULTS: Our approach allows us to estimate the commercial value of generating additional data (the difference between the estimated net present value of stick and twist). We test the sensitivity of the results to different assumptions via scenario analyses. CONCLUSIONS: This article shows that simulation methods can be used to help pharmaceutical managers make informed strategic decisions in contexts of uncertainty.
Assuntos
Antineoplásicos Imunológicos/economia , Antineoplásicos Imunológicos/uso terapêutico , Orçamentos , Contratos/economia , Tomada de Decisões , Técnicas de Apoio para a Decisão , Aprovação de Drogas/economia , Custos de Medicamentos , Desenvolvimento de Medicamentos/economia , Negociação , Avaliação da Tecnologia Biomédica/economia , Antineoplásicos Imunológicos/efeitos adversos , Simulação por Computador , Análise Custo-Benefício , Alocação de Recursos para a Atenção à Saúde/economia , Humanos , Modelos Econômicos , Modelos Estatísticos , Formulação de Políticas , Resultado do Tratamento , IncertezaRESUMO
BACKGROUND: The cost of developing a new drug is approximately USD 2.6 billion, and over two-thirds of the total cost is embedded in the clinical-testing phase. Patient recruitment is the single biggest cause of clinical trial delays, and these delays can result in up to USD 8 million per day in lost revenue for pharmaceutical companies. Further, clinical trials struggle to keep participants engaged in the study and as many as 40% drop out. To overcome these challenges pharmaceutical companies and research institutions (e.g., universities) increasingly use an emerging concept: virtual clinical trials (VCT) based on a remote approach. SUMMARY: VCT (site-less) are a relatively new method of conducting a clinical trial, taking full advantage of technology (apps, monitoring devices, etc.) and inclusion of web platforms (recruitment, informed consent, counselling, measurement of endpoints, and any adverse reactions) to allow the patient to be home-based at every stage of the clinical trial. Studies have shown that VCT are not only operationally feasible, but also successful. They have higher recruitment rates, better compliance, lower drop-out rates, and are conducted faster than traditional clinical trials. The visual nature of dermatological conditions, the relative ease in evaluating skin diseases virtually, and the fact that skin diseases often are not life-threatening and rarely require complex examinations make VCT very attractive for dermatological research. Further, making correct diagnoses based on photographs and patient symptomatology has always been part of the dermatologist's routine. Thus, VCT are in many ways made for dermatology. Herein we describe VCT and their implications in dermatological research.
Assuntos
Ensaios Clínicos como Assunto , Fármacos Dermatológicos , Dermatologia , Desenvolvimento de Medicamentos , Telemedicina , Pesquisa Biomédica/economia , Pesquisa Biomédica/métodos , Ensaios Clínicos como Assunto/economia , Ensaios Clínicos como Assunto/métodos , Fármacos Dermatológicos/efeitos adversos , Fármacos Dermatológicos/economia , Fármacos Dermatológicos/uso terapêutico , Dermatologia/economia , Dermatologia/métodos , Desenvolvimento de Medicamentos/economia , Desenvolvimento de Medicamentos/métodos , Humanos , Seleção de Pacientes , Telemedicina/economia , Telemedicina/métodosRESUMO
AIM: To analyze the late-stage failures of monoclonal antibody drugs. The later a drug fails in development, the more time and expense is incurred by the sponsor. METHODS: We review the late stage, Phase III, failures of 21 monoclonal antibody drugs between 2014 and 2019 using published and publicly available information to characterize the reasons for these failures. RESULTS: In some cases, the failures are unavoidable due to the lack of adequate science, but in others, we characterize the causes of such failures and recommend how such failures may have been avoided. CONCLUSION: By learning from previous mistakes and adhering to the principles and recommendations provided, it is possible to avoid these common pitfalls, increasing the likelihood of success in phase III clinical trials, and thus securing regulatory approval.
Assuntos
Anticorpos Monoclonais/administração & dosagem , Desenvolvimento de Medicamentos/métodos , Animais , Ensaios Clínicos Fase III como Assunto/métodos , Desenvolvimento de Medicamentos/economia , Humanos , Estudos Retrospectivos , Falha de TratamentoRESUMO
There are two major problems with the development of therapies for rare diseases. First, among over 7000 such diseases, the vast majority are caused by genetic defects and/or include neurodegeneration, making them very difficult to treat. Second, drugs for rare diseases, so-called orphan drugs, are extremely expensive, as only a small number of patients are interested in purchasing them. This results in the appearance of a specific economic trap of rare diseases; namely, despite high biomedical, pharmaceutical and technological potential, the development of new orphan drugs is blocked by the economic reality. The purpose of this work was to find a potential solution that might resolve this economic trap of rare diseases. A literature review was conducted, and a hypothesis was formulated assuming that the use of one drug for the treatment of many rare diseases might overcome the economic trap. We provide examples showing that finding such drugs is possible. Thus, a possible solution for the problem of developing orphan drugs is presented. Further preclinical and clinical studies, although neither easy nor inexpensive, should verify whether the hypothesis regarding the possibility of unlocking the economic trap of rare diseases is valid.
Assuntos
Efeitos Psicossociais da Doença , Análise Custo-Benefício/métodos , Produção de Droga sem Interesse Comercial/economia , Doenças Raras/tratamento farmacológico , Doenças Raras/economia , Desenvolvimento de Medicamentos/economia , Humanos , Preparações Farmacêuticas/administração & dosagem , Preparações Farmacêuticas/economiaRESUMO
BACKGROUND: The frameworks used by Health Technology Assessment (HTA) agencies for value assessment of medicines aim to optimize healthcare resource allocation. However, they may not be effective at capturing the value of antimicrobial drugs. OBJECTIVES: To analyze stakeholder perceptions regarding how antimicrobials are assessed for value for reimbursement purposes and how the Australian HTA framework accommodates the unique attributes of antimicrobials in cost-effectiveness evaluation. METHODS: Eighteen individuals representing the pharmaceutical industry or policy-makers were interviewed. Interviews were transcribed verbatim, coded, and thematically analyzed. RESULTS: Key emergent themes were that reimbursement decision-making should consider the antibiotic spectrum when assessing value, risk of shortages, the impact of procurement processes on low-priced comparators, and the need for methodological transparency when antimicrobials are incorporated into the economic evaluation of other treatments. CONCLUSIONS: Participants agreed that the current HTA framework for antimicrobial value assessment is inadequate to properly inform funding decisions, as the contemporary definition of cost-effectiveness fails to explicitly incorporate the risk of future resistance. Policy-makers were uncertain about how to incorporate future resistance into economic evaluations without a systematic method to capture costs avoided due to good stewardship. Lacking financial reward for the benefits of narrower-spectrum antimicrobials, companies will likely focus on developing broad-spectrum agents with wider potential use. The perceived risks of shortages have influenced the funding of generic antimicrobials in Australia, with policy-makers suggesting a willingness to pay more for assured supply. Although antibiotics often underpin the effectiveness of other medicines, it is unclear how this is incorporated into economic models.
Assuntos
Anti-Infecciosos/economia , Anti-Infecciosos/uso terapêutico , Desenvolvimento de Medicamentos/organização & administração , Avaliação da Tecnologia Biomédica/organização & administração , Pessoal Administrativo , Anti-Infecciosos/provisão & distribuição , Austrália , Análise Custo-Benefício , Desenvolvimento de Medicamentos/economia , Indústria Farmacêutica/organização & administração , Humanos , Reembolso de Seguro de Saúde/normas , Entrevistas como Assunto , Modelos EconômicosRESUMO
IMPORTANCE: The mean cost of developing a new drug has been the subject of debate, with recent estimates ranging from $314 million to $2.8 billion. OBJECTIVE: To estimate the research and development investment required to bring a new therapeutic agent to market, using publicly available data. DESIGN AND SETTING: Data were analyzed on new therapeutic agents approved by the US Food and Drug Administration (FDA) between 2009 and 2018 to estimate the research and development expenditure required to bring a new medicine to market. Data were accessed from the US Securities and Exchange Commission, Drugs@FDA database, and ClinicalTrials.gov, alongside published data on clinical trial success rates. EXPOSURES: Conduct of preclinical and clinical studies of new therapeutic agents. MAIN OUTCOMES AND MEASURES: Median and mean research and development spending on new therapeutic agents approved by the FDA, capitalized at a real cost of capital rate (the required rate of return for an investor) of 10.5% per year, with bootstrapped CIs. All amounts were reported in 2018 US dollars. RESULTS: The FDA approved 355 new drugs and biologics over the study period. Research and development expenditures were available for 63 (18%) products, developed by 47 different companies. After accounting for the costs of failed trials, the median capitalized research and development investment to bring a new drug to market was estimated at $985.3 million (95% CI, $683.6 million-$1228.9 million), and the mean investment was estimated at $1335.9 million (95% CI, $1042.5 million-$1637.5 million) in the base case analysis. Median estimates by therapeutic area (for areas with ≥5 drugs) ranged from $765.9 million (95% CI, $323.0 million-$1473.5 million) for nervous system agents to $2771.6 million (95% CI, $2051.8 million-$5366.2 million) for antineoplastic and immunomodulating agents. Data were mainly accessible for smaller firms, orphan drugs, products in certain therapeutic areas, first-in-class drugs, therapeutic agents that received accelerated approval, and products approved between 2014 and 2018. Results varied in sensitivity analyses using different estimates of clinical trial success rates, preclinical expenditures, and cost of capital. CONCLUSIONS AND RELEVANCE: This study provides an estimate of research and development costs for new therapeutic agents based on publicly available data. Differences from previous studies may reflect the spectrum of products analyzed, the restricted availability of data in the public domain, and differences in underlying assumptions in the cost calculations.
Assuntos
Desenvolvimento de Medicamentos/economia , Indústria Farmacêutica/economia , Pesquisa Farmacêutica/economia , Custos e Análise de Custo/estatística & dados numéricos , Custos de Medicamentos , Indústria Farmacêutica/estatística & dados numéricos , Estados Unidos , United States Food and Drug AdministrationRESUMO
Importance: Understanding the profitability of pharmaceutical companies is essential to formulating evidence-based policies to reduce drug costs while maintaining the industry's ability to innovate and provide essential medicines. Objective: To compare the profitability of large pharmaceutical companies with other large companies. Design, Setting, and Participants: This cross-sectional study compared the annual profits of 35 large pharmaceutical companies with 357 companies in the S&P 500 Index from 2000 to 2018 using information from annual financial reports. A statistically significant differential profit margin favoring pharmaceutical companies was evidence of greater profitability. Exposures: Large pharmaceutical vs nonpharmaceutical companies. Main Outcomes and Measures: The main outcomes were revenue and 3 measures of annual profit: gross profit (revenue minus the cost of goods sold); earnings before interest, taxes, depreciation, and amortization (EBITDA; pretax profit from core business activities); and net income, also referred to as earnings (difference between all revenues and expenses). Profit measures are described as cumulative for all companies from 2000 to 2018 or annual profit as a fraction of revenue (margin). Results: From 2000 to 2018, 35 large pharmaceutical companies reported cumulative revenue of $11.5 trillion, gross profit of $8.6 trillion, EBITDA of $3.7 trillion, and net income of $1.9 trillion, while 357 S&P 500 companies reported cumulative revenue of $130.5 trillion, gross profit of $42.1 trillion, EBITDA of $22.8 trillion, and net income of $9.4 trillion. In bivariable regression models, the median annual profit margins of pharmaceutical companies were significantly greater than those of S&P 500 companies (gross profit margin: 76.5% vs 37.4%; difference, 39.1% [95% CI, 32.5%-45.7%]; P < .001; EBITDA margin: 29.4% vs 19%; difference, 10.4% [95% CI, 7.1%-13.7%]; P < .001; net income margin: 13.8% vs 7.7%; difference, 6.1% [95% CI, 2.5%-9.7%]; P < .001). The differences were smaller in regression models controlling for company size and year and when considering only companies reporting research and development expense (gross profit margin: difference, 30.5% [95% CI, 20.9%-40.1%]; P < .001; EBITDA margin: difference, 9.2% [95% CI, 5.2%-13.2%]; P < .001; net income margin: difference, 3.6% [95% CI, 0.011%-7.2%]; P = .05). Conclusions and Relevance: From 2000 to 2018, the profitability of large pharmaceutical companies was significantly greater than other large, public companies, but the difference was less pronounced when considering company size, year, or research and development expense. Data on the profitability of large pharmaceutical companies may be relevant to formulating evidence-based policies to make medicines more affordable.